Compound tirzepatide for weight loss: what the evidence shows

What did @pinkmathteacher actually say?

She made three core claims: compound tirzepatide is weaker than brand-name Mounjaro but "better than having nothing," it sits somewhere between Ozempic and Mounjaro in effectiveness, and it has not helped her break a weight stall over the past month. She also compared the cost favorably against bariatric surgery and said compound tirzepatide is "the only compound weight loss medication worth purchasing." These are specific, personal claims mixed with broader efficacy comparisons that deserve scrutiny.

She was transparent about her source (Zippi Health, $360/month) and her uncertainty about continuing. That honesty matters. But some of her comparisons, particularly ranking compound tirzepatide above semaglutide ("better than Ozempic") and claiming it performs like the 24-48 hour window before a Mounjaro dose, are informal subjective readings, not pharmacological fact.

Does the science back this up?

Partially, but the ranking claim is the weakest part. Head-to-head trial data does not support a simple tirzepatide-above-semaglutide-above-liraglutide hierarchy for every patient, and there is essentially no published clinical data on compounded tirzepatide specifically.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieved up to 22.5% mean body weight reduction at 72 weeks, which outperformed semaglutide outcomes in the STEP 1 trial (Wilding et al., 2021, NEJM) at around 14.9%. So brand-name tirzepatide does outperform brand-name semaglutide on average at a population level. But compounded tirzepatide is a different product. The FDA has repeatedly noted that compounded drugs are not FDA-approved and have not been evaluated for safety or efficacy. A compounded preparation could vary in concentration, excipients, and stability. Saying the compound sits neatly between two brand-name drugs assumes a precision in formulation that has not been independently verified.

Her description of feeling "something suppressing appetite" is consistent with tirzepatide's dual GIP/GLP-1 receptor agonism, which does produce satiety signaling. That part is biologically plausible.

What did they get wrong (or right)?

She got the general efficacy ranking directionally right for brand-name drugs, but applied it incorrectly to the compound version. There is no clinical basis for placing compounded tirzepatide at a specific midpoint between brand-name drugs. That framing implies a standardization the product does not have.

She also got the cost comparison roughly right. Bariatric surgery costs range from $15,000 to $25,000 out of pocket according to ASMBS estimates, and monthly GLP-1 costs, even at $360-$500, are lower if treatment duration is under two years. That math checks out directionally.

What she said wrong or imprecisely: calling compound tirzepatide "better than Ozempic" is an unverifiable claim. No direct clinical comparison exists. Her personal experience on compound tirzepatide cannot be generalized to semaglutide outcomes in other patients. Presenting it as a general ranking misleads viewers who might switch medications based on a TikTok.

Credit where it is due: she did not claim the compound cured anything, she acknowledged uncertainty, and she was honest that it has not broken her weight stall. That kind of hedging is rare in GLP-1 content.

What should you actually know?

Compounded tirzepatide is in a legally complicated and clinically unverified space. The FDA placed tirzepatide on its shortage list in 2023, which temporarily allowed compounding pharmacies to legally produce it. That status has shifted, and the FDA has been working to remove tirzepatide from shortage designation, which would make most compounded versions legally questionable under federal law.

The core issue for patients is quality control. A 503B outsourcing facility operates under stricter FDA oversight than a standard compounding pharmacy. If you are using compounded tirzepatide, the source matters enormously. Not all compounding pharmacies are equivalent, and potency, sterility, and dosing consistency are real variables.

Weight stalls on GLP-1 medications are common and well documented. Aroda et al. (2022, Diabetes Care) noted that plateau periods occur across GLP-1 classes and are not necessarily a sign the medication is failing. Dose titration, dietary composition, and baseline metabolic rate all interact with outcomes. A stall at the same dose is expected behavior, not proof the compound is inferior.

• Talk to a licensed prescriber before switching between brand-name and compounded GLP-1 products.
• Verify your compounding pharmacy's 503A or 503B status.
• Do not use another patient's weight loss experience to predict your own outcome.

The bottom line

This creator is sharing genuine personal experience, which has value. But the claim that compound tirzepatide is definitively "better than Ozempic" is not supported by evidence and should not guide anyone's medication decisions. The cost comparison to bariatric surgery is reasonable math. The efficacy ranking is not. Use this video as one data point from one person's lived experience, not as a clinical guide.